Retmarker is a leading company that specializes in the development of proprietary Artificial Intelligence (AI) technology for the screening and monitoring of retinal diseases. With a focus on vision loss prevention, Retmarker's innovative AI technology is revolutionizing the field. Retinal diseases, such as Diabetic Retinopathy and Age-Related Macular Degeneration (AMD), are among the leading causes of blindness in the Western world.

Retmarker offers a range of products and services to address these conditions. Their highly reliable and affordable Diabetic Retinopathy Screening technology is accessible to providers worldwide. By analyzing multiple retinal images taken over time, their AI-powered DR Biomarker predicts sight-threatening complications associated with Diabetic Retinopathy, making it a valuable tool for clinical trials and research.

In addition, Retmarker's advanced image analysis capabilities support the study and annotation of AMD lesions, aiding in the understanding and treatment of this condition. Certified as a class IIa medical device in Europe and approved in Australia, Retmarker's technology has demonstrated its effectiveness through extensive testing and has received recognition in independent studies. With its cutting-edge AI technology, Retmarker is at the forefront of vision loss prevention and is committed to making a positive impact on global eye health.

Don't wait, reach out to Retmarker today to learn more about their groundbreaking technology